This site is intended for U.S. Healthcare Professionals only.
Request a Rep
*POETYK PSO-1 (N=664) and POETYK PSO-2 (N=1020) were two, 52-week, multicenter, randomized, double-blind, placebo- and active (apremilast 30 mg twice daily)-controlled, Phase 3 studies to evaluate the safety and efficacy of SOTYKTU (6 mg once daily) in adult patients with moderate-to-severe plaque psoriasis. See additional study design details.1
†Co-primary endpoints: percentage of patients achieving PASI 75 at Week 16 vs placebo and percentage of patients achieving sPGA 0/1 vs placebo at Week 16. The results were achieved for PASI 75 (POETYK PSO-1: 58% vs 13%; POETYK PSO-2: 53% vs 9%) and sPGA 0/1 (POETYK PSO-1: 54% vs 7%; POETYK PSO-2: 50% vs 9%). Statistical significance was achieved for secondary endpoint PASI 75 vs apremilast at Week 16 (POETYK PSO-1: 58% vs 35%; POETYK PSO-2: 53% vs 40%).1
PASI=psoriasis area and severity index; PASI 75=75% reduction from baseline in PASI; sPGA 0/1=statistic Physician’s Global Assessment, patients achieving clear (0) or almost clear (1) skin.
SOTYKTU tablet is not actual size. Shown for illustrative purposes only.
SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
are trademarks of Bristol-Myers Squibb Company.
© 2023 Bristol-Myers Squibb Company.
Otezla is a registered trademark of Amgen Inc